PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of diseaseFast Track Designation recognizes the potential of ...

Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, ...

In this context, conductive foam serves as a key "electromagnetic pathway" connecting the battery module casing and the ...

U.S. Customs and Border Protection officials detected cesium 137 in shipping containers of shrimp sent by PT Bahari Makmur Sejati to several U.S. ports. CBP officials flagged the potential ...

Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines, and pressure from US President Donald Trump ...

Trump said he will put tariffs of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on ...

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering ...